|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lombard DB, Schwer B, Alt FW and
Mostoslavsky R: SIRT6 in DNA repair, metabolism and ageing. J
Intern Med. 263:128–141. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sebastián C, Satterstrom FK, Haigis MC and
Mostoslavsky R: From sirtuin biology to human diseases: An update.
J Biol Chem. 287:42444–42452. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tennen RI and Chua KF: Chromatin
regulation and genome maintenance by mammalian SIRT6. Trends
Biochem Sci. 36:39–46. 2011. View Article : Google Scholar
|
|
5
|
Michishita E, McCord RA, Berber E, Kioi M,
Padilla-Nash H, Damian M, Cheung P, Kusumoto R, Kawahara TL,
Barrett JC, et al: SIRT6 is a histone H3 lysine 9 deacetylase that
modulates telomeric chromatin. Nature. 452:492–496. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ran LK, Chen Y, Zhang ZZ, Tao NN, Ren JH,
Zhou L, Tang H, Chen X, Chen K, Li WY, et al: SIRT6 overexpression
potentiates apoptosis evasion in hepatocellular carcinoma via
BCL2-associated X protein-dependent apoptotic pathway. Clin Cancer
Res. 22:3372–3382. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sebastián C, Zwaans BM, Silberman DM,
Gymrek M, Goren A, Zhong L, Ram O, Truelove J, Guimaraes AR, Toiber
D, et al: The histone deacetylase SIRT6 is a tumor suppressor that
controls cancer metabolism. Cell. 151:1185–1199. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Min L, Ji Y, Bakiri L, Qiu Z, Cen J, Chen
X, Chen L, Scheuch H, Zheng H, Qin L, et al: Liver cancer
initiation is controlled by AP-1 through SIRT6-dependent inhibition
of survivin. Nat Cell Biol. 14:1203–1211. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Marquardt JU, Fischer K, Baus K, Kashyap
A, Ma S, Krupp M, Linke M, Teufel A, Zechner U, Strand D, et al:
Sirtuin-6-dependent genetic and epigenetic alterations are
associated with poor clinical outcome in hepatocellular carcinoma
patients. Hepatology. 58:1054–1064. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lefort K, Brooks Y, Ostano P, Cario-André
M, Calpini V, Guinea-Viniegra J, Albinger-Hegyi A, Hoetzenecker W,
Kolfschoten I, Wagner EF, et al: A miR-34a SIRT6 axis in the
squamous cell differentiation network. EMBO J. 32:2248–2263. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu Y, Xie QR, Wang B, Shao J, Zhang T,
Liu T, Huang G and Xia W: Inhibition of SIRT6 in prostate cancer
reduces cell viability and increases sensitivity to
chemotherapeutics. Protein Cell. 4:702–710. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lau NC, Lim LP, Weinstein EG and Bartel
DP: An abundant class of tiny RNAs with probable regulatory roles
in Caenorhabditis elegans. Science. 294:858–862. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lee RC and Ambros V: An extensive class of
small RNAs in Caenorhabditis elegans. Science. 294:862–864. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Farazi TA, Hoell JI, Morozov P and Tuschl
T: MicroRNAs in human cancer. Adv Exp Med Biol. 774:1–20. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fu J, Tang W, Du P, Wang G, Chen W, Li J,
Zhu Y, Gao J and Cui L: Identifying microRNA-mRNA regulatory
network in colorectal cancer by a combination of expression profile
and bioinformatics analysis. BMC Syst Biol. 6:682012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dotto GP and Karine L: miR-34a/SIRT6 in
squamous differentiation and cancer. Cell Cycle. 13:1055–1056.
2014. View
Article : Google Scholar :
|
|
17
|
Ding W, Hu W, Yang H, Ying T and Tian Y:
Prognostic correlation between MTA2 expression level and colorectal
cancer. Int J Clin Exp Pathol. 8:7173–7180. 2015.PubMed/NCBI
|
|
18
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
20
|
Feng J, Yan PF, Zhao HY, Zhang FC, Zhao WH
and Feng M: SIRT6 suppresses glioma cell growth via induction of
apoptosis, inhibition of oxidative stress and suppression of
JAK2/STAT3 signaling pathway activation. Oncol Rep. 35:1395–1402.
2016. View Article : Google Scholar
|
|
21
|
Xu JH, Zhang C, Tang B, Hao YX, Chen J,
Liu T and Cui H: Effect of JAK2/STAT3/vimentin signaling pathway on
proliferation and migration of human colon cancer cells. Zhonghua
Wei Chang Wai Ke Za Zhi. 13:282–285. 2010.In Chinese. PubMed/NCBI
|
|
22
|
Lu YM, Chen W, Zhu JS, Chen WX and Chen
NW: Eriocalyxin B blocks human SW1116 colon cancer cell
proliferation, migration, invasion, cell cycle progression and
angiogenesis via the JAK2/STAT3 signaling pathway. Mol Med Rep.
13:2235–2240. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu X, Ji Q, Ye N, Sui H, Zhou L, Zhu H,
Fan Z, Cai J and Li Q: Berberine inhibits invasion and metastasis
of colorectal cancer cells via COX-2/GE2 mediated JAK2/STAT3
signaling pathway. PLoS One. 10:e01234782015. View Article : Google Scholar
|
|
24
|
Chae IG, Kim DH, Kundu J, Jeong CH, Kundu
JK and Chun KS: Generation of ROS by CAY10598 leads to inactivation
of STAT3 signaling and induction of apoptosis in human colon cancer
HCT116 cells. Free Radic Res. 48:1311–1321. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhou J, Wu A, Yu X, Zhu J and Dai H: SIRT6
inhibits growth of gastric cancer by inhibiting JAK2/STAT3 pathway.
Oncol Rep. 38:1059–1066. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kara M, Yumrutas O, Ozcan O, Celik OI,
Bozgeyik E, Bozgeyik I and Tasdemir S: Differential expressions of
cancer-associated genes and their regulatory miRNAs in colorectal
carcinoma. Gene. 567:81–86. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kawahara TL, Michishita E, Adler AS,
Damian M, Berber E, Lin M, McCord RA, Ongaigui KC, Boxer LD, Chang
HY, et al: SIRT6 links histone H3 lysine 9 deacetylation to
NF-kappaB-dependent gene expression and organismal life span. Cell.
136:62–74. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xiao C, Kim HS, Lahusen T, Wang RH, Xu X,
Gavrilova O, Jou W, Gius D and Deng CX: SIRT6 deficiency results in
severe hypoglycemia by enhancing both basal and insulin-stimulated
glucose uptake in mice. J Biol Chem. 285:36776–36784. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kim HS, Xiao C, Wang RH, Lahusen T, Xu X,
Vassilopoulos A, Vazquez-Ortiz G, Jeong WI, Park O, Ki SH, et al:
Hepatic-specific disruption of SIRT6 in mice results in fatty liver
formation due to enhanced glycolysis and triglyceride synthesis.
Cell Metab. 12:224–236. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kugel S, Sebastián C, Fitamant J, Ross KN,
Saha SK, Jain E, Gladden A, Arora KS, Kato Y, Rivera MN, et al:
SIRT6 Suppresses Pancreatic Cancer through Control of Lin28b. Cell.
165:1401–1415. 2016. View Article : Google Scholar :
|
|
31
|
Bauer I, Grozio A, Lasigliè D, Basile G,
Sturla L, Magnone M, Sociali G, Soncini D, Caffa I, Poggi A, et al:
The NAD+-dependent histone deacetylase SIRT6 promotes
cytokine production and migration in pancreatic cancer cells by
regulating Ca2+ responses. J Biol Chem. 287:40924–40937.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang G, Liu Z, Qin S and Li K: Decreased
expression of SIRT6 promotes tumor cell growth correlates closely
with poor prognosis of ovarian cancer. Eur J Gynaecol Oncol.
36:629–632. 2015. View Article : Google Scholar
|
|
33
|
Han Z, Liu L, Liu Y and Li S: Sirtuin
SIRT6 suppresses cell proliferation through inhibition of Twist1
expression in non-small cell lung cancer. Int J Clin Exp Pathol.
7:4774–4781. 2014.PubMed/NCBI
|
|
34
|
Dai PC, Liu DL, Zhang L, Ye J, Wang Q,
Zhang HW, Lin XH and Lai GX: Astragaloside IV sensitizes non-small
cell lung cancer cells to gefitinib potentially via regulation of
SIRT6. Tumour Biol. 39:10104283176975552017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Azuma Y, Yokobori T, Mogi A, Altan B,
Yajima T, Kosaka T, Onozato R, Yamaki E, Asao T, Nishiyama M, et
al: SIRT6 expression is associated with poor prognosis and
chemosensitivity in patients with non-small cell lung cancer. J
Surg Oncol. 112:231–237. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bai L, Lin G, Sun L, Liu Y, Huang X, Cao
C, Guo Y and Xie C: Upregulation of SIRT6 predicts poor prognosis
and promotes metastasis of non-small cell lung cancer via the
ERK1/2/MMP9 pathway. Oncotarget. 7:40377–40386. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Qu N, Hu JQ, Liu L, Zhang TT, Sun GH, Shi
RL and Ji QH: SIRT6 is upregulated and associated with cancer
aggressiveness in papillary thyroid cancer via BRAF/ERK/Mcl 1
pathway. Int J Oncol. 50:1683–1692. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tao NN, Ren JH, Tang H, Ran LK, Zhou HZ,
Liu B, Huang AL and Chen J: Deacetylation of Ku70 by SIRT6
attenuates Bax-mediated apoptosis in hepatocellular carcinoma.
Biochem Biophys Res Commun. 485:713–719. 2017. View Article : Google Scholar
|
|
39
|
Lee N, Ryu HG, Kwon JH, Kim DK, Kim SR,
Wang HJ, Kim KT and Choi KY: SIRT6 Depletion Suppresses Tumor
Growth by Promoting Cellular Senescence Induced by DNA Damage in
HCC. PLoS One. 11:e01658352016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang ZG and Qin CY: Sirt6 suppresses
hepatocellular carcinoma cell growth via inhibiting the
extracellular signal regulated kinase signaling pathway. Mol Med
Rep. 9:882–888. 2014. View Article : Google Scholar
|
|
41
|
Rizzo A, Iachettini S, Salvati E, Zizza P,
Maresca C, D'Angelo C, Benarroch-Popivker D, Capolupo A, Del Gaudio
F, Cosconati S, et al: SIRT6 interacts with TRF2 and promotes its
degradation in response to DNA damage. Nucleic Acids Res.
45:1820–1834. 2017. View Article : Google Scholar :
|
|
42
|
Penrose H, Heller S, Cable C, Makboul R,
Chadalawada G, Chen Y, Crawford SE and Savkovic SD: Epidermal
growth factor receptor mediated proliferation depends on increased
lipid droplet density regulated via a negative regulatory loop with
FOXO3/Sirtuin6. Biochem Biophys Res Commun. 469:370–376. 2016.
View Article : Google Scholar
|
|
43
|
Lin Z, Yang H, Tan C, Li J, Liu Z, Quan Q,
Kong S, Ye J, Gao B and Fang D: USP10 antagonizes c-Myc
transcriptional activation through SIRT6 stabilization to suppress
tumor formation. Cell Reports. 5:1639–1649. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang X, Qiu W, Zhang G, Xu S, Gao Q and
Yang Z: MicroRNA-204 targets JAK2 in breast cancer and induces cell
apoptosis through the STAT3/BCl-2/survivin pathway. Int J Clin Exp
Pathol. 8:5017–5025. 2015.PubMed/NCBI
|
|
45
|
Tung SL, Huang WC, Hsu FC, Yang ZP, Jang
TH, Chang JW, Chuang CM, Lai CR and Wang LH: miRNA-34c-5p inhibits
amphiregulin-induced ovarian cancer stemness and drug resistance
via downregulation of the AREG-EGFR-ERK pathway. Oncogenesis.
6:e3262017. View Article : Google Scholar :
|
|
46
|
Catuogno S, Cerchia L, Romano G, Pognonec
P, Condorelli G and de Franciscis V: miR-34c may protect lung
cancer cells from paclitaxel-induced apoptosis. Oncogene.
32:341–351. 2013. View Article : Google Scholar
|
|
47
|
Wu H, Huang M, Lu M, Zhu W, Shu Y, Cao P
and Liu P: Regulation of microtubule-associated protein tau (MAPT)
by miR-34c-5p determines the chemosensitivity of gastric cancer to
paclitaxel. Cancer Chemother Pharmacol. 71:1159–1171. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Li G, Qiu Y, Su Z, Ren S, Liu C, Tian Y
and Liu Y: Genome-wide analyses of radioresistance-associated miRNA
expression profile in nasopharyngeal carcinoma using next
generation deep sequencing. PLoS One. 8:e844862013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Luo Z, Zhang L, Li Z, Li X, Li G, Yu H,
Jiang C, Dai Y, Guo X, Xiang J, et al: An in silico analysis of
dynamic changes in microRNA expression profiles in stepwise
development of nasopharyngeal carcinoma. BMC Med Genomics. 5:32012.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Re M, Çeka A, Rubini C, Ferrante L, Zizzi
A, Gioacchini FM, Tulli M, Spazzafumo L, Sellari-Franceschini S,
Procopio AD, et al: MicroRNA-34c-5p is related to recurrence in
laryngeal squamous cell carcinoma. Laryngoscope. 125:E306–E312.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Li F, Chen H, Huang Y, Zhang Q, Xue J, Liu
Z and Zheng F: miR-34c plays a role of tumor suppressor in HEC 1-B
cells by targeting E2F3 protein. Oncol Rep. 33:3069–3074. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Wu Z, Wu Y, Tian Y, Sun X, Liu J, Ren H,
Liang C, Song L, Hu H, Wang L, et al: Differential effects of
miR-34c-3p and miR-34c-5p on the proliferation, apoptosis and
invasion of glioma cells. Oncol Lett. 6:1447–1452. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
López JA and Alvarez-Salas LM:
Differential effects of miR-34c-3p and miR-34c-5p on SiHa cells
proliferation apoptosis, migration and invasion. Biochem Biophys
Res Commun. 409:513–519. 2011. View Article : Google Scholar : PubMed/NCBI
|
